A5088135455- Treatment of Major Depression
- Tryptophan and brain disorders
- Functional Brain Connectivity Studies
- Neurotransmitter Receptor Influence on Behavior
- Mental Health Research Topics
- Bipolar Disorder and Treatment
- Electroconvulsive Therapy Studies
- MicroRNA in disease regulation
- Neuroscience and Neuropharmacology Research
- Obsessive-Compulsive Spectrum Disorders
- Posttraumatic Stress Disorder Research
- BIM and Construction Integration
- Alcoholism and Thiamine Deficiency
- Prion Diseases and Protein Misfolding
- Attention Deficit Hyperactivity Disorder
- Psychedelics and Drug Studies
- Neurological disorders and treatments
- Suicide and Self-Harm Studies
- Anesthesia and Neurotoxicity Research
- Genetic Neurodegenerative Diseases
- Pharmaceutical Practices and Patient Outcomes
- 3D Surveying and Cultural Heritage
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Child Abuse and Trauma
- Transcranial Magnetic Stimulation Studies
Universidade Federal da Bahia
2017-2024
Complexo Hospitalar Universitário Professor Edgard Santos
2019-2024
Escola Bahiana de Medicina e Saúde Pública
2021
Introduction: The use of ketamine as an option in the treatment depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, S (+) enantiomer ketamine, most widely used form anesthetic environment some countries, new studies have shown that it may also be effective depression with better tolerability. However, no study so far has directly compared esketamine racemic ketamine. Here we propose a protocol trial to evaluate...
Abstract Background Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) characterized by the failure at least one adequate trial major class antidepressant, with time dosage. We aimed to identify clinical predictors remission response 24 h 7 days after racemic ketamine esketamine infusions. Methods A randomized, double‐blind, active‐controlled, non‐inferiority using in TRD....
This study evaluated efficacy and safety of intravenous subanesthetic doses esketamine using an administration time 10 minutes in patients with treatment-resistant depression bipolar depression.A retrospective chart review was conducted to identify who met the inclusion criteria for according Diagnostic Statistical Manual Mental Disorders, Fourth Edition, Text Revision criteria, these received rapid infusion between June 2012 December 2015. The Montgomery-Åsberg Depression Rating Scale...
Objective Converging evidence supports the role of glutamate, an excitatory amino acid neurotransmitter, in pathophysiology obsessive-compulsive disorder (OCD). Ketamine and esketamine, both noncompetitive N -methyl- d -aspartate antagonists, have emerged as a promising medication for this psychiatric disorder, given its possible efficacy with faster onset good tolerability. The purpose retrospective chart review is to evaluate whether unbiased clinical documentation formal trials esketamine...
Background Ketamine and esketamine have both shown significant antidepressant effects in treatment-resistant depression (TRD), conflicting evidence suggests that induced dissociation by these drugs can be a clinical predictor of esketamine/ketamine's efficacy.
Abstract Purposes/Background The aims of the study were to assess subanesthetic esketamine as an antidepressant for major depressive disorder with psychotic features (PMDD) and compare posttreatment symptoms among those PMDD a sample nonpsychotic depression (major [MDD]). Methods/Procedures This is retrospective chart review patients current symptoms, treated single parenteral 0.5-mg/kg dose esketamine. Depression assessed at baseline 24-hour Montgomery-Åsberg Rating Scale. Individuals...
Past suicide attempt (SA) is one of the most important risk factors for death. An ideation-to-action framework posits that impulsivity, potentially traumatic events, and mental disorders also play a role in increasing risk. This study aimed to assess association between trait lifetime exposure trauma, post-traumatic stress disorder (PTSD) with SA sample Brazilian college students.A total 2,137 participants filled self-reported questionnaires consisting sociodemographic clinical...
Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact ketamine and esketamine serum BDNF levels association with response patterns treatment-resistant depression (TRD).
Despite the hardships of major depressive disorder (MDD), biomarkers for diagnosis and pharmacological management this condition are lacking. MicroRNAs epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize findings validation selection use specific microRNAs as in treatment MDD. A systematic review conducted using PubMed/MEDLINE, Cochrane, PsycINFO, Embase, LILACS databases from March May 2022, with clusters terms based on microRNA antidepressant....
This study aimed to evaluate the effect of genetic variants in glutamate ionotropic receptor N-methyl- d -aspartate type subunit 2B ( GRIN2B ), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 1 GRIA1 and brain-derived neurotrophic factor BDNF ) genes on therapeutic response, remission, total Montgomery-Åsberg Depression Rating Scale scores after treatment with ketamine or esketamine treatment-resistant depression (TRD) patients.Participants (N = 60) are from a double-blind, randomized,...